We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Destiny Pharma Plc | LSE:DEST | London | Ordinary Share | GB00BDHSP575 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.50 | -2.99% | 16.25 | 16.00 | 16.50 | 16.75 | 15.00 | 16.75 | 1,383,597 | 14:39:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -6.5M | -0.0683 | -2.34 | 15.24M |
From Apr 2019 to Apr 2024
TIDMDEST
RNS Number : 5084A
Destiny Pharma PLC
29 December 2017
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Total Voting Rights
As a result of the issue of 1,910,828 shares at GBP1.57 each to China Medical Venture Investments, which raised GBP3 million for the Company, and which was announced on 1 December 2017, the Company announces that, pursuant to Rule 5.6.1 of the FCA's Disclosure Guidance and Transparency Rules, the total number of ordinary shares in issue now stands at 43,562,598, and the total number of voting rights in the Company is 43,562,598.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Destiny Pharma
Neil Clark, CEO
Simon Sacerdoti, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell / Hanna Skeppner
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Broker)
Philip Davies / Will Goode, Corporate Finance
pdavies@cantor.co.uk
+44 (0)20 7894 8337
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the WHO and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRDMMZZVRLGNZM
(END) Dow Jones Newswires
December 29, 2017 02:00 ET (07:00 GMT)
1 Year Destiny Pharma Chart |
1 Month Destiny Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
